Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Decitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 known ✓ | P26358 | 6/20 | 0.91 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.91 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | GMNN | O75496 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | THPO | P40225 | 1/20 | 0.57 |
| ▸ | MTOR | P42345 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | HBB | P68871 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | PNP | P00491 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | PIM1 | P11309 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Decitabine SCHEMBL3396534 | 1.00 | DNMT1 (0.91) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL4006 | 0.95 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL661233 | 0.95 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL18402620 | 0.95 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL1651086 | 0.95 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL117721 | 0.95 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL12800474 | 0.95 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL20769771 | 0.95 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL20651628 | 0.95 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT | |
| Decitabine SCHEMBL172264 | 0.95 | DNMT1 (1.00) | DNMT1ADRB1LMNATP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11965164-B2 | Amphiphilic polynucleotides | DUKE UNIVERSITY (US) | 2024-04-23 | — | — | US | disclosed |
| EP-4316494-A1 | COMBINED THERAPY OF 4'-THIO-5-AZA-2'-DEOXYCYTIDINE AND VENETOCLAX | Pinotbio, Inc. (KR) | 2024-02-07 | — | — | EP | disclosed |
| CN-117412757-A | Combination therapy of 4 '-thio-5-aza-2' -deoxycytidine and valnemulin | 匹诺生物股份有限公司 | 2024-01-16 | — | — | CN | disclosed |
| EP-3861992-B1 | COMBINATION THERAPY COMPRISING PLANT DERIVED COMPOUNDS AND ANTINEOPLASTIC COMPOUNDS FOR TREATMENT OF HEMATOLOGICAL MALIGNANCIES | CANNAFAMILY A S (CZ) | 2023-09-06 | — | — | EP | disclosed |
| US-20230183699-A1 | AMPHIPHILIC POLYNUCLEOTIDES | DUKE UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| WO-2023014045-A1 | MEDICINAL USE OF 4'-THIO-5-AZA-2'-DEOXYCYTIDINE SELECTED AS WELL-DESIGNED MULTI-TARGET INHIBITOR | 주식회사 피노바이오 | 2023-02-09 | — | — | WO | disclosed |
| US-11512314-B2 | Amphiphilic polynucleotides | DUKE UNIVERSITY (US) | 2022-11-29 | — | — | US | disclosed |
| US-11478444-B2 | Use of scientifically matched plant supplements combined with antineoplastic compounds for the treatment of hematological malignancies | Brio Ventures (US) | 2022-10-25 | — | — | US | disclosed |
| WO-2022215995-A1 | COMBINED THERAPY OF 4'-THIO-5-AZA-2'-DEOXYCYTIDINE AND VENETOCLAX | 주식회사 피노바이오 | 2022-10-13 | — | — | WO | disclosed |
| US-20210244703-A1 | USE OF SCIENTIFICALLY MATCHED PLANT SUPPLEMENTS COMBINED WITH ANTINEOPLASTIC COMPOUNDS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES | Brio Ventures, LLC (US) | 2021-08-12 | — | — | US | disclosed |
| EP-3861992-A1 | COMBINATION THERAPY COMPRISING PLANT DERIVED COMPOUNDS AND ANTINEOPLASTIC COMPOUNDS FOR TREATMENT OF HEMATOLOGICAL MALIGNANCIES | Brio Ventures, LLC (US) | 2021-08-11 | — | — | EP | disclosed |
| US-20210009999-A1 | AMPHIPHILIC POLYNUCLEOTIDES | NATIONAL SCIENCE FOUNDATION | 2021-01-14 | — | — | US | disclosed |
| US-20190054103-A1 | METHOD OF TREATMENT OF TP53 WILD-TYPE TUMORS WITH 2',2'-DIFLUORO-5-AZA-2'-DEOXYCYTIDINE OR PRODRUGS THEREOF | EPIGENETICS PHARMA, LLC | 2019-02-21 | — | — | US | disclosed |
| EP-3419631-A1 | METHOD OF TREATMENT OF TP53 WILD-TYPE TUMORS WITH 2',2'-DIFLUORO-5-AZA-2'-DEOXYCYTIDINE OR PRODRUGS THEREOF | Epigenetics Pharma, LLC (US) | 2019-01-02 | — | — | EP | disclosed |
| WO-2017143453-A1 | METHOD OF TREATMENT OF TP53 WILD-TYPE TUMORS WITH 2',2'-DIFLUORO-5-AZA-2'-DEOXYCYTIDINE OR PRODRUGS THEREOF | EPIGENETICS PHARMA, LLC (US) | 2017-08-31 | — | — | WO | disclosed |
| WO-2013112948-A1 | BENCHMARKS FOR NORMAL CELL IDENTIFICATION | NODALITY, INC. (US) | 2013-08-01 | — | — | WO | disclosed |
| WO-2012033537-A1 | BENCHMARKS FOR NORMAL CELL IDENTIFICATION | NODALITY, INC. (US) | 2012-03-15 | — | — | WO | disclosed |
| US-20070105792-A1 | Administration Of DNA Methylation Inhibitors For Treating Epigenetic Diseases | SUPERGEN, INC. | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11965164-B2 | Amphiphilic polynucleotides | NCL, APLNR, POLN | DNMT1 1018/4885ADRB1 2834/4885LMNA 247/4885 |
| US-20210009999-A1 | AMPHIPHILIC POLYNUCLEOTIDES | NCL, APLNR, POLN | DNMT1 1018/4885ADRB1 2834/4885LMNA 247/4885 |
| US-20190054103-A1 | METHOD OF TREATMENT OF TP53 WILD-TYPE TUMORS WITH 2',2'-DIFLUORO-5-AZA-2'-DEOXYCYTIDINE OR PRODRUGS THEREOF | TP53, TP53BP1, MDM2 | DNMT1 9/4885ADRB1 4861/4885LMNA 3931/4885 |
| US-20230183699-A1 | AMPHIPHILIC POLYNUCLEOTIDES | NCL, APLNR, POLN | DNMT1 1018/4885ADRB1 2834/4885LMNA 247/4885 |
| US-11512314-B2 | Amphiphilic polynucleotides | NCL, APLNR, POLN | DNMT1 1018/4885ADRB1 2834/4885LMNA 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.